At 4.9% CAGR, the Middle East & Africa Clinical Trials Market is Projected to be Worth US$ 1,803.78 Million by 2031, Says Business Market Insights

According to Business Market Insights research, the Middle East & Africa clinical trials market was valued at US$ 1,234.57 million in 2023 and is expected to reach US$ 1,803.78 million by 2031, registering a CAGR of 4.9% from 2023 to 2031. AI-driven clinical trials and practice of outsourcing clinical studies with massive rise in number of trials are among the critical factors attributed to the Middle East & Africa clinical trials market expansion.

The adoption of artificial intelligence (AI) offers innovative ways to collect and manage clinical trial data, along with reducing dependency on manual operations. Thus, AI acts as a game changer for life science companies involved in the drug development process. AstraZeneca has collected oncology data, including clinical and imaging data, of more than 100,000 patients consenting for different clinical studies. The Oncology Data Science team at AstraZeneca feeds these data into a system that utilizes AI and other statistical tools to generate novel hypotheses for oncology drug development. To transform the process of oncology data feed, the team is adopting complex datasets for accessibility, interoperability, and reusability of data as per the GO FAIR principles, which emphasize on making data findable, accessible, interoperable, and reusable. Such integration empowers data collection from specific clinical trials and projects to be accessible across the company's drug development teams in compliance with data protection laws.

In November 2021, AstraZeneca collaborated with Tempus to leverage real-world data and represent patients globally. This strategic partnership focuses on offering crucial evidence about patient outcomes without revealing the identification of the clinical trial participants in the datasets. Moreover, with the power of AI, companies can rapidly digitize clinical trial processes to complete studies faster. Life-saving medicines and treatments can be provided to patients more quickly, and life sciences companies could gain a competitive edge. According to Deloitte's life sciences digital innovation survey 2023, 76% of respondents invested in AI for clinical development. Thus, AI-driven clinical trials, involving the use of AI for processing clinical trial data, are emerging as significant trends in the clinical trial market.

On the contrary, expensive and time-consuming process hampers the growth of Middle East & Africa clinical trials market.

Based on study design, the Middle East & Africa clinical trials market is bifurcated into interventional trials and expanded access trials. The interventional trials segment held 89.5% share of the Middle East & Africa clinical trials market in 2023, amassing US$ 1,104.88 million. It is projected to garner US$ 1,644.53 million by 2031 to expand at 5.1% CAGR during 2023–2031.

Based on indications, the Middle East & Africa clinical trials market is segmented into autoimmune/inflammation, pain management, oncology, neurological disorders, diabetes, obesity, metabolic disorders, cardiovascular, and others. The oncology segment held 27.7% share of the Middle East & Africa clinical trials market in 2023, amassing US$ 341.38 million. It is projected to garner US$ 523.24 million by 2031 to expand at 5.5% CAGR during 2023–2031.

Based on phase type, the Middle East & Africa clinical trials market is segmented into phase I, phase II, and phase III. The phase II segment held 49.7% share of the Middle East & Africa clinical trials market in 2023, amassing US$ 613.17 million. It is projected to garner US$ 920.15 million by 2031 to expand at 5.2% CAGR during 2023–2031.

Based on country, the Middle East & Africa clinical trials market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. South Africa held 41.7% share of Middle East & Africa clinical trials market in 2023, amassing US$ 514.46 million. It is projected to garner US$ 798.04 million by 2031 to expand at 5.6% CAGR during 2023–2031.

Key players operating in the clinical trials market are QVIA Holdings Inc, Parexel International Corp, IXICO Plc, Charles River Laboratories International Inc, ICON Plc, WuXi AppTec Co Ltd, SGS SA, Syneos Health Inc, Thermo Fisher Scientific Inc, Laboratory Corp of America Holdings, CliniRx Research Private Limited, Caidya, Oracle Corp, Medpace Holdings Inc, and SIRO Clinpharm Pvt Ltd, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com